Interior minister says ammonium nitrate likely caused at least one explosion amid reports hospitals too damaged to treat patients.
Category: biotech/medical – Page 1672
It’s no secret that healthcare costs have risen faster than inflation for decades. Some experts estimate that healthcare will account for over 20% of the US GDP by 2025. Meanwhile, doctors are working harder than ever before to treat patients as the U.S. physician shortage continues to grow. Many medical professionals have their schedules packed so tightly that much of the human element which motivated their pursuit of medicine in the first place is reduced.
In healthcare, artificial intelligence (AI) can seem intimidating. At the birthday party of a radiologist friend, she gently expressed how she felt her job would be threatened by AI in the coming decade. Yet, for most of the medical profession, AI will be an accelerant and enabler, not a threat. It would be good business for AI companies as well to help, rather than attempt to replace, medical professionals.
In a previous article, I expressed three ways in which I consistently see AI adding value: speed, cost and accuracy. In healthcare, it’s no different. Here are three examples of how AI will change healthcare.
Consuming a single dose of the psychedelic brew ayahuasca can result in lasting changes in higher-order cognitive brain networks, according to a new study published in the Journal of Psychopharmacology.
Ayahuasca, a concoction used for centuries by indigenous Amazon tribes, contains the powerful psychedelic drug dimethyltryptamine (DMT) and monoamine oxidase inhibitors. The brew is typically prepared using leaves from the Psychotria viridis shrub and the bark of the Banisteriopsis caapi vine.
The new neuroimaging research suggests that ayahuasca may produce long-lasting effects on mood by altering the functional connectivity of the brain’s salience and default mode networks.
To that end, Barry Prentice, who leads the Canadian company Buoyant Aircraft Systems International, hopes to use airships to transport pre-built structures for schools and housing to remote parts of Canada that lack good roads.
And earlier this year, French airship company Flying Whales (I mean, how can you not adore that name?) received $23 million in funding from the government of Quebec to build cargo-carrying Zeppelins.
Given our current pandemic-dominated reality, it’s hard to imagine a future of seamless global travel of any kind, much less on an airship. But that future will, thankfully, arrive (though when is anyone’s guess). As calls for climate action get louder and the costs associated with airships drop—as the cost of any new technology tends to do with time—we may find ourselves going retro and being ferried across the globe by giant helium-filled balloons.
TEL AVIV — Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said Sunday.
Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, or aviptadil, a synthetic form of a natural peptide that protects the lung. US-Israeli NeuroRx Inc. partnered with Relief to develop the drug in the United States.
In June the US Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19.
READ: Avalon GloboCare forges partnership with Austrian university to develop coronavirus vaccine
It noted that treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent.
Purdue University innovators are working on inventions to use micro-chip technology in implantable devices and other wearable products such as smart watches to improve biomedical devices, including those used to monitor people with glaucoma and heart disease.
The Purdue team developed a fully implantable radio-frequency transmitter chip for wireless sensor nodes and biomedical devices. The research is published in the journal IEEE Transactions on Circuits and Systems II. The transmitter chip consumes lowest amount of energy per digital bit published to date.
The transmitter works in a similar fashion to communication technology in mobile phones and smart watches, but the Purdue transmitter has an unprecedented level of miniaturization and low-energy consumption that it can be implanted into an eye to monitor pressure for a glaucoma patient or into another part of the body to measure data related to heart functions.
Singapore researchers have developed “electronic skin” capable of recreating a sense of touch, an innovation they hope will allow people with prosthetic limbs to detect objects, as well as feel texture, or even temperature and pain.
The device, dubbed ACES, or Asynchronous Coded Electronic Skin, is made up of 100 small sensors and is about 1 square centimeter (0.16 square inch) in size.
The researchers at the National University of Singapore say it can process information faster than the human nervous system, is able to recognise 20 to 30 different textures and can read Braille letters with more than 90% accuracy.
DARPA’s Subterranean (SubT) Challenge focuses on discovering innovative approaches to map, navigate, and search complex underground environments across three diverse subdomains: human-made tunnels, urban underground, and natural cave systems. Two previous scored events – Tunnel and Urban Circuits – featured both Virtual and Systems Competitions. DARPA has made the difficult decision to proceed only with the Virtual Competition for the Cave Circuit, due to safety considerations surrounding COVID-19. The date for the Cave Circuit Virtual Competition webcast/public event will be announced in the coming weeks.
Teams must qualify by a September 15 deadline to participate in the Cave Circuit Virtual Competition, which includes team registration and registration on the SubT Challenge Virtual Portal. Additional details are available in the SubT Qualification Guide available on the program’s Resources Page. Interested teams also are encouraged to join the SubT Community Forum, where they can engage with other participants and ask any questions.
“We recognize and share the teams’ passion to compete and showcase the hard work they have completed since the Urban Circuit, and we also are committed to the safety of the global community and extended SubT Challenge family,” said Dr. Timothy Chung, program manager for the SubT Challenge in DARPA’s Tactical Technology Office. “Additionally, I know a significant aspect of the SubT Challenge is the opportunity to invite the public to experience the camaraderie and competition unique to DARPA challenges. We look forward to providing greater insight into the Virtual Competition Cave Circuit via an enhanced webcast and online experience, and offering additional opportunities to experience the SubT Challenge during the Final Event.”
Two California companies were selected for DARPA’s Gamma Ray Inspection Technology (GRIT) program and have begun work to develop a transportable, tunable source of gamma rays for a host of national security, industrial, and medical applications.
Lumitron Technologies and RadiaBeam Technologies started work on the GRIT program in April and are exploring novel approaches to achieve high-intensity, tunable, and narrow-bandwidth sources of gamma ray radiation in a compact, transportable form factor.
GRIT aims to provide a source of tunable, pure x-rays and gamma rays from tens of keV (kilo-electron volts) up through three MeV (mega-electron volts). Currently, tunable and narrow bandwidth gamma ray sources only exist at highly specialized user facilities best suited for basic research and are not able to support broad practical applications. Shrinking these photon sources to a transportable system is the major goal and challenge of the GRIT program.